Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

NCT02466711
View directory record Official record
Conditions
Gastric Motility
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Local Anesthesia and Pain Perception During an Amniocentesis

NCT00583011
View directory record Official record
Conditions
Pregnancy
Interventions
Local Anesthesia, Placebo Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

NCT05292911
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Montclair, California • Sacramento, California • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Results available

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

NCT05128071
View directory record Official record
Conditions
Methamphetamine-dependence, Postpartum Abstinence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

An Evaluation of Protective Effects of OpalSeal™ Against Early Dental Decay in Orthodontic Patients

NCT03722264
View directory record Official record
Conditions
Cavities of Teeth
Interventions
OpalSeal, TransbondXT
Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
10 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

NCT05071664
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Searcy, Arkansas • Avon Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Safer Still (Exploratory Project 3)

NCT06558409
View directory record Official record
Conditions
Suicide Prevention
Interventions
" Safer Still " Interactive Intervention, Enhanced Usual Care (EUC):
Behavioral · Other
Lead sponsor
Jeff Bridge
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 22, 2026, 10:45 PM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

NCT05224063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuronavigated rTMS, Sham rTMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

NCT06680375
View directory record Official record
Conditions
COVID-19
Interventions
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo
Combination Product · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
9
States / cities
Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 10:45 PM EDT
Not yet recruiting Phase 3 Interventional

Study of Serine Supplementation to Protect Vision in MacTel

NCT07342439
View directory record Official record
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
L-serine, Placebo
Drug · Other
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
La Jolla, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT05289557
View directory record Official record
Conditions
Morning Sickness
Interventions
Bonjesta, Placebo
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Burbank, California • Hialeah, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome

NCT02067819
View directory record Official record
Conditions
Tourette Syndrome, Chronic Tic Disorder
Interventions
Active Oral Orthotic Treatment, Placebo Oral Orthotic Treatment
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
7 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 22, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

NCT05027919
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Use Disorder, Opioid Craving
Interventions
Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, Lofexidine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 22, 2026, 10:45 PM EDT
Active, not recruiting Phase 3 Interventional

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430
View directory record Official record
Conditions
Hypertension
Interventions
lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
128
States / cities
Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

NCT04452500
View directory record Official record
Conditions
PTSD
Interventions
CORT108297, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 10:45 PM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 22, 2026, 10:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171
View directory record Official record
Conditions
Hypertension, Renal Transplant
Interventions
Placebo, Allopurinol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 22, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 22, 2026, 10:45 PM EDT